## NBIX: Neurocrine Biosciences, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.27 indicates fundamental undervaluation. Caution: momentum weakening (-2.1% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($138.13)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Is Neurocrine Biosciences (NBIX) Quietly Recasting Its Long-Term Story Around Metabolic Disease Innovation?**
- Source: Simply Wall Street | 20251220T020903 | Somewhat-Bullish | Relevance: 100%
- Neurocrine Biosciences is diversifying its R&D strategy by extending its CRF platform into metabolic diseases, including obesity, alongside its neuropsychiatry programs. This move aims to reshape the company's long-term product mix and reduce concentration risk from its existing commercial base. The company projects significant revenue and earnings growth by 2028, with a fair value indicating a 23% upside from its current price.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | HC Wainwright & | $198 | $168 | +18% |
| 2025-12-12 | Mizuho | $175 | $146 | +20% |
| 2025-12-11 | Stifel | $188 | $183 | +3% |
| 2025-12-08 | RBC Capital | $180 | $160 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | HC Wainwright & | main | Buy |
| 2025-12-12 | Mizuho | main | Neutral |
| 2025-12-11 | Stifel | main | Buy |
| 2025-12-08 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 10 ($2.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 12.7% (-1.9%)
- Vanguard Group Inc: 9.7% (-1.0%)
- JPMORGAN CHASE & CO: 9.5% (+122.0%)
- Dodge & Cox Inc.: 5.6% (-0.2%)
- State Street Corpora: 4.4% (-2.7%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.1% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.27 indicates undervaluation relative to growth. Forward P/E 16.0x attractive for 33% earnings growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (3.4x), low leverage (D/E 0.42). Analyst sentiment positive (5 raises, avg +13%). Insider selling cluster ($3.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.7B |
| Beta | 0.27 |
| 52W Range | $84.23 - $160.18 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.27 |
| Forward P/E | 16.0 |
| Current P/E | 21.3 |
| YoY Growth | 33.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.2% to -2.4% (-2.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.4pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.14x) but short-term weakness (below SMA20). MACD histogram bearish (-1.23), momentum weakening. RSI neutral at 49. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.38% (CS: 23) | Weak |
| RSI_14 | 48.8 | Neutral |
| MACD Histogram | -1.23 | Bearish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 1.010x | Above |
| vs SMA200 | 1.136x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $147.53
- **Stop Loss:** $138.13 (6.4% risk)
- **Target:** $166.33 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 127
- **Position Value:** $18,736.31
- **Portfolio %:** 18.74%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-05 (Est: $2.41)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.07 | $2.17 | +4.9% |
| 2025Q2 | $1.50 | $1.65 | +9.6% |
| 2025Q1 | $1.09 | $0.70 | -36.0% |
| 2024Q4 | $1.93 | $1.69 | -12.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*